Strengthening Our Portfolio of Transmission Electron Microscopes for the Pharmaceutical Industry Through Investment to Vironova AB

Hitachi High-Technologies Corporation (TSE:8036/Hitachi High-Tech) have undertaken a third-party allotment of shares (this capital alliance) with Vironova AB (Main office: Stockholm, Sweden /CEO: Mohammed Homman/Vironova), who develop and sell analysis software for transmission electron microscopes (TEM) along with carrying out contract analysis for pharmaceutical companies. Through this capital alliance, we aim to jointly develop TEM... Read more

GE Healthcare Life Sciences and Akeso Pharmaceuticals to speed up novel therapy manufacturing in China

GE Healthcare Life Sciences will supply Akeso Pharmaceuticals with the FlexFactory™ platform to accelerate the production of antibody drugs in the Guangzhou region Expected to be operational by end of 2020 and create up to 150 jobs upon opening. November 6, 2019 – Uppsala, Sweden and Guangzhou, China – Akeso Pharmaceuticals, a biotech company specializing... Read more

Thermo Fisher Scientific Highlights Expanded Pharma Services Capabilities During CPhI

Thermo Fisher Scientific Highlights Expanded Pharma Services Capabilities During CPhI Strategic investments support efforts to bring advanced medicines to market faster FRANKFURT, Germany, Nov. 5, 2019 /PRNewswire/ — CPhI 2019 — Thermo Fisher Scientific, the world leader in serving science, will highlight recent initiatives to expand its capabilities, capacity and talent globally at the 2019 CPhI Worldwide conference.... Read more

SIEMENS HEALTHINEERS ENTERS INTO LICENSE AND SUPPLY ARRANGEMENT WITH QUANTERIX FOR ACCESS TO NEUROFILAMENT LIGHT (NF-L) ANTIBODIES TO DEVELOP NF-L ASSAYS

NOVEMBER 04, 2019 BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a licensing and supply arrangement with Siemens Healthineers for access to Quanterix’ proprietary Nf-L antibodies, which were recently acquired from UmanDiagnostics. Access to the Nf-L antibodies will allow Siemens... Read more

GE Healthcare announces U.S. FDA approval of macrocyclic MRI contrast agent Clariscan™ (gadoterate meglumine) injection for intravenous use

Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products  Chalfont St Giles, UK – November 4 2019 – The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast... Read more

Bruker Launches Ultrafast FTIR Imaging Microscope LUMOS II

ETTLINGEN, Germany, October 28, 2019 – Bruker today announced the launch of the novel, stand-alone FTIR (Fourier Transform Infrared) imaging microscope LUMOS II, which provides ultrafast FTIR imaging capabilities using focal-plane array (FPA) detectors in its high-end version. The new, automated LUMOS II is designed to identify particles, to determine coatings and contaminations, and to... Read more

MKS Announces Release of Ultra-Fast C-Series Mass Flow Controllers

Delivering ultra-fast response time for high precision flow control Andover, Mass., – October 22, 2019 – MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of technologies that enable advanced processes and improve productivity, today announced the release of its next generation C-Series Mass Flow Controllers. C-Series Ultrafast Mass Flow Controller The C-Series Mass Flow Controller uses... Read more

Danaher Reaches Agreement To Sell Certain Businesses To Sartorius AG As Part Of The GE Biopharma Acquisition Regulatory Process

Danaher Reaches Agreement To Sell Certain Businesses To Sartorius AG As Part Of The GE Biopharma Acquisition Regulatory Process WASHINGTON, Oct. 21, 2019 /PRNewswire/ — Danaher Corporation (NYSE: DHR) today announced that it has signed an agreement to sell its label-free biomolecular characterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses to... Read more

Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications

Basel, 18 October 2019 Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at... Read more